Skip to main content

Table 2 Biochemistry

From: Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Parameter

Placebo

Apabetalone

P value

HbA1c

 Baseline (%)

7.3 (6.4–8.6)

7.4 (6.4–8.7)

 

 Follow up (%)

7.2 (6.4–8.4)

7.2 (6.4–8.5)

 

 Absolute change (%)

0.00 [− 0.10, 0.05]

− 0.05 [− 0.15, 0.00]

0.18

 Percent change (%)

0.04 [− 0.76, 0.88]

− 0.63 [− 1.49, 0.25]

0.25

LDL-C

 Baseline (mg/dL)

70.9 ± 32.4

69.7 ± 29.8

 

 Follow up (mg/dL)

63.6 ± 29.4

63.4 ± 28.3

 

 Absolute change (mg/dL)

− 6.55 [− 8.00, − 5.10]

− 6.34 [− 7.79, − 4.89]

0.37

 Percent change (%)

− 0.31 [− 4.13, 3.50]

− 1.57 [− 2.25, 5.38]

0.28

HDL-C

 Baseline (mg/dL)

33.3 ± 5.1

33.3 ± 5.1

 

 Follow up (mg/dL)

36.6 ± 7.5

38.0 ± 8.0

 

 Absolute change (mg/dL)

3.34 [2.93, 3.75]

4.75 [4.34, 5.15]

< 0.0001

 Percent change (%)

10.9 [9.62, 12.2]

15.4 [14.1, 16.7]

< 0.0001

hsCRP

 Baseline (mg/L)

2.7 (1.1–6.1)

2.9 (1.3–5.9)

 

 Follow up (mg/L)

1.8 (1.0–4.3)

1.8 (0.9–3.9)

 

 Absolute change (mg/L)

− 0.53 [− 0.93, − 0.24]

− 0.80 [− 1.3, − 0.44]

0.34

 Percent change (%)

− 11.3 [− 20.0, − 1.5]

− 18.4 [− 28.0, − 7.1]

0.16

ALP

 Baseline (U/L)

81.9 ± 34.7

83.3 ± 38.2

 

 Follow up (U/L)

79.5 ± 29.5

74.3 ± 43.2

 

 Absolute change (U/L)

− 2.20 [− 3.60, − 0.81]

− 8.98 [− 10.4, − 7.59]

< 0.0001

 Percent change (%)

4.22 [0.27, 8.18]

− 8.31 [− 12.2, − 4.37]

< 0.0001

eGFR

 Baseline (mL/min)

102 ± 38.6

105 ± 39.2

 

 Follow up (mL/min)

105 ± 40.2

106 ± 41.9

 

 Absolute change (mL/min)

2.02 [0.97, 3.07]

− 0.33 [− 1.38, 1.72]

0.001

 Percent change (%)

3.03 [1.87, 4.18]

− 0.46 [− 0.70, 1.61]

0.001

  1. Biochemical parameters at baseline and change after 24 weeks (12 weeks for CRP) of treatment with apabetalone or placebo. Baseline means ± SDs or medians (IQR) are shown. For absolute and percent change, estimates with [95% CIs] are given
  2. ALP alkaline phosphatase, HbA1c glycated haemoglobin, HDL-C high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein (assessed in only a subset of patients), LDL-C low-density lipoprotein cholesterol, eGFR estimated glomerular filtration rate